Zura Bio (NASDAQ:ZURA) Research Coverage Started at Piper Sandler

Piper Sandler initiated coverage on shares of Zura Bio (NASDAQ:ZURA) in a research note published on Friday morning, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $26.00 price objective on the stock.

Separately, Oppenheimer restated an outperform rating and issued a $16.00 target price (down from $17.00) on shares of Zura Bio in a report on Monday, April 1st. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zura Bio currently has an average rating of Buy and an average target price of $18.00.

Zura Bio Trading Up 6.0 %

Shares of NASDAQ:ZURA opened at $4.62 on Friday. Zura Bio has a one year low of $2.00 and a one year high of $14.00. The business’s fifty day moving average price is $3.26 and its two-hundred day moving average price is $3.95.

Insider Buying and Selling

In other news, Director Amit Munshi bought 159,744 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The shares were acquired at an average cost of $3.13 per share, with a total value of $499,998.72. Following the transaction, the director now owns 777,384 shares of the company’s stock, valued at approximately $2,433,211.92. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have purchased 170,926 shares of company stock valued at $534,998. Insiders own 15.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ZURA. Armistice Capital LLC grew its position in Zura Bio by 66.3% in the third quarter. Armistice Capital LLC now owns 1,580,000 shares of the company’s stock valued at $10,428,000 after acquiring an additional 630,000 shares in the last quarter. Silverarc Capital Management LLC boosted its stake in shares of Zura Bio by 152.5% in the third quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock valued at $2,667,000 after purchasing an additional 244,040 shares during the period. Eisler Capital US LLC acquired a new stake in Zura Bio during the 3rd quarter valued at $660,000. Bank of New York Mellon Corp purchased a new stake in Zura Bio during the 3rd quarter worth $224,000. Finally, Forefront Analytics LLC acquired a new position in Zura Bio in the 3rd quarter worth $95,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.